Celgene Drug Improves PFS in Phase III Melanoma Study
Celgene Drug Improves PFS in Phase III Melanoma Study
Filed under: drug treatment news 2011
Celgene separately today reported its results for the third quarter of 2012, which included global Abraxane sales of $ 106 million, down 6% on the same period in 2011. U.S. sales of Abraxane, at $ 81 million, were down 14%. International of the drug were …
Read more on Genetic Engineering News
European Regulators Grant Conditional Approval for Pfizer's Xalkori; Abbott …
Filed under: drug treatment news 2011
The drug is indicated as a treatment for advanced NSCLC patients who have been previously treated and whose tumors have rearrangements in the ALK gene. The US Food and Drug Administration approved Xalkori in August 2011, with a companion test …
Read more on GenomeWeb
More drug treatment news 2011 Resources
… Fetch Content
celgene corp munster, p. 72081 saic-frederick m. arkin sfgh aids-shaman pharm sp303t study 61228 sfgh aids-applied imm sc/phase 2 st drug study-burr/wellcome 566c80 61965 s/m sfgh-syntex corp-ganciclovir … Retrieve Full Source
Celgene Management Discusses Q3 2012 Results – Earnings Call Transcript
Executives Patrick FlaniganRobert J. Hugin – Chairman, Chief Executive Officer, President and Chairman of Executive CommitteeJacqualyn A. Fouse – Chief Financial Officer, Chief Accounting Officer and Executive … Read News
… Read Document
TX: VcR-CVAD Phase 2 Study (Velcade + Rituxan + Cyclophosphamide + Doxorubicin + He's probably going to put me on a low dose of prednisone, a nasty drug which I've been fortunate enough to avoid so far, since my CHOP days. … Fetch This Document